Investing Insights: Bill Ackman’s Recent Picks
Bill Ackman, founder and CEO of Pershing Square Capital Management, has consistently outperformed the S&P 500. His recent stock purchases in Netflix and Uber Technologies have garnered attention, especially considering both stocks have faced significant declines (33% for Netflix and 18% for Uber over the past year).
1. Netflix (NFLX)
Current Price: $79.59
Market Cap: $331B
Recent Trends: Netflix has seen slower revenue growth and disappointing guidance. Notably, they plan to release engagement reports annually starting in 2027, raising concerns about their ability to monetize effectively.
Reasons to Stay Bullish:
- Adaptability: Netflix has a history of overcoming challenges like increased competition and password-sharing through new initiatives, such as a low-priced ad-supported tier.
- Growth Opportunities: The company is looking to expand into sports streaming and possibly launch live TV, leveraging its extensive ecosystem and viewer data.
- Advertising Revenue: Netflix expects ad revenue to double by 2025, indicating strong potential growth.
Overall, the stock seems like a promising buy on the dip.
2. Uber Technologies (UBER)
Current Price: $78.80
Market Cap: $161B
Recent Concerns: Uber’s second-quarter performance disappointed many, citing weak revenue growth and a significant focus on AI investments, with fears of obsolescence due to rising autonomous vehicle technology.
Positive Outlook:
- AI Investments: Despite recent layoffs (10% of the customer service workforce), Uber’s emphasis on AI could lead to lower operational costs and better profit margins.
- Robotaxi Market: Uber’s deal with Rivian to obtain 50,000 autonomous EVs starting in 2028 positions the company to potentially dominate the future transport landscape.
Despite current setbacks, Uber’s growth potential and strategic initiatives make it an attractive buy on the dip.
In conclusion, both Netflix and Uber, while facing headwinds, show signs of resilience and adaptability—qualities that could translate into long-term growth opportunities for patient investors.
